The order carried out as a part of the project titled:
– YKL-40: “DEVELOPMENT OF A FIRST-IN-CLASS SMALL MOLECULE DRUG CANDIDATE FOR CANCER TREATMENT THROUGH YKL40 INHIBITION” (POIR.01.01.01-00-0552/16)
co-financed by European Union Funds and because of the competitiveness principle.
We hereby look for Contractor ready to perform the service:
Expert advice and consulting in the area of biological and translational research, including the role of CHIT3L1 (YKL-40) and CHIT1 proteins in lung diseases, in particular in (also COVID-19 induced) lung fibrosis, as well as testing OAT compounds in animal models.
On October 27, 2020, the Ordering Party introduces a change regarding the extension of the deadline for submitting offers. The change is marked in red. The Appendices have not been changed.